VIVUS LLC
SpecialtyVIVUS LLC is a specialty pharmaceutical company focused on Metabolic, Cardiovascular, Respiratory. Key products include QSYMIA.
VIVUS LLC at a Glance
- Strong track record with 91% execution quality across 35 trials
- Fast trial execution (7 months median completion)
VIVUS LLC's Key Drugs
VIVUS LLC's core commercial portfolio centers on QSYMIA, STENDRA, spanning Metabolic and Cardiovascular — its most strategically important drugs approved in the last 15 years.
VIVUS LLC's Recent FDA Approvals
New NDA/BLA approvals for VIVUS LLC over the last two years — novel drugs only, excluding generics and label supplements.
VIVUS LLC's Therapeutic Areas
VIVUS LLC's approved drugs and pipeline span 5 therapeutic areas, led by Metabolic and Cardiovascular, across 1 biologic and 2 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
VIVUS LLC's Top Competitors
VIVUS LLC's closest competitors by therapeutic-area and drug-target overlap include Merck, AZURITY, and AstraZeneca. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
VIVUS LLC Pipeline Snapshot
VIVUS LLC has 12 active clinical programs from ClinicalTrials.gov — 3 Phase 3, 5 Phase 2 and 4 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • QSYMIA leads revenue
- • 2 key drugs tracked
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/5 completed
- • Speed: 7 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges